Aclaris Therapeutics, Inc.
(NASDAQ : ACRS)

( )
ACRS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -2.41%43.410.0%$636.11m
GWPHGW Pharmaceuticals Plc 0.36%214.946.1%$394.55m
VRXValeant Pharmaceuticals International, Inc. 3.39%32.9814.1%$194.06m
HZNPHorizon Therapeutics Plc 2.85%88.655.5%$192.84m
JAZZJazz Pharmaceuticals Plc 2.68%164.752.3%$186.19m
BHCBausch Health Cos., Inc. 3.39%32.980.0%$148.25m
CTLTCatalent, Inc. 1.33%104.452.1%$106.06m
ICLRICON plc 4.55%179.834.2%$95.66m
PRGOPerrigo Co. Plc 1.31%41.106.8%$73.07m
ARGXargenx SE -0.53%289.750.0%$71.68m
TNXPTonix Pharmaceuticals Holding Corp. 5.37%1.020.2%$57.10m
ZYNEZynerba Pharmaceuticals, Inc. 1.47%4.156.0%$54.26m
AMRNAmarin Corp. Plc 4.72%5.991.5%$43.81m
UTHRUnited Therapeutics Corp. 2.50%164.3414.1%$43.26m
PBHPrestige Consumer Healthcare, Inc. 2.69%43.594.0%$42.48m

Company Profile

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.